"Lung Neoplasms/therapy"[Major] OR (Lung Cancer[ti] AND (treat*[ti] OR therapy[ti])) AND (systematic review[pt] OR review[pt]) AND free full text[sb] AND "last 2 years"[dp] AND English[la] - Search Results

Year	Number of Results
2002	4
2019	1
2020	6
2021	293
2022	473
2023	207

1

Proteolysis targeting chimeras in non-small cell lung cancer.

Hagopian G, Grant C, Nagasaka M. Hagopian G, et al. Cancer Treat Rev. 2023 Jun;117:102561. doi: 10.1016/j.ctrv.2023.102561. Epub 2023 Apr 26. Cancer Treat Rev. 2023. PMID: 37178629 Free article. Review.

2

Pre-clinical modelling of ROS1+ non-small cell lung cancer.

Terrones M, de Beeck KO, Van Camp G, Vandeweyer G. Terrones M, et al. Lung Cancer. 2023 Jun;180:107192. doi: 10.1016/j.lungcan.2023.107192. Epub 2023 Apr 11. Lung Cancer. 2023. PMID: 37068393 Free article. Review.

3

Approaches and outcomes of Robotic-Assisted Thoracic Surgery (RATS) for lung cancer: a narrative review.

Mattioni G, Palleschi A, Mendogni P, Tosi D. Mattioni G, et al. J Robot Surg. 2023 Jun;17(3):797-809. doi: 10.1007/s11701-022-01512-8. Epub 2022 Dec 21. J Robot Surg. 2023. PMID: 36542242 Free PMC article. Review.

4

The artificial intelligence and machine learning in lung cancer immunotherapy.

Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T. Gao Q, et al. J Hematol Oncol. 2023 May 24;16(1):55. doi: 10.1186/s13045-023-01456-y. J Hematol Oncol. 2023. PMID: 37226190 Free PMC article. Review.

5

Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer.

Buma AIG, Schuurbiers MMF, van Rossum HH, van den Heuvel MM. Buma AIG, et al. Tumour Biol. 2023 May 23. doi: 10.3233/TUB-220034. Online ahead of print. Tumour Biol. 2023. PMID: 36710691 Free article. Review.

6

Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.

Chen Y, Luo H, Liu R, Tan M, Wang Q, Wu X, Du T, Liu Z, Sun S, Zhang Q, Wang X. Chen Y, et al. Radiat Oncol. 2023 May 22;18(1):86. doi: 10.1186/s13014-023-02264-x. Radiat Oncol. 2023. PMID: 37217970 Free PMC article. Review.

7

Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review.

Park SD, Kim MS, Han MH, Kim YJ, Jung HY, Choi JY, Cho JH, Park SH, Kim CD, Kim YL, Lim JH. Park SD, et al. Medicina (Kaunas). 2023 May 21;59(5):991. doi: 10.3390/medicina59050991. Medicina (Kaunas). 2023. PMID: 37241223 Free PMC article. Review.

8

Radiomics and artificial intelligence for precision medicine in lung cancer treatment.

Chen M, Copley SJ, Viola P, Lu H, Aboagye EO. Chen M, et al. Semin Cancer Biol. 2023 May 19;93:97-113. doi: 10.1016/j.semcancer.2023.05.004. Online ahead of print. Semin Cancer Biol. 2023. PMID: 37211292 Free article. Review.

9

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.

Liu W, Huo G, Chen P. Liu W, et al. BMC Cancer. 2023 May 19;23(1):458. doi: 10.1186/s12885-023-10959-3. BMC Cancer. 2023. PMID: 37202730 Free PMC article.

10

Lipid Nanocarrier-Based Drug Delivery Systems: Therapeutic Advances in the Treatment of Lung Cancer.

Kim SJ, Puranik N, Yadav D, Jin JO, Lee PCW. Kim SJ, et al. Int J Nanomedicine. 2023 May 18;18:2659-2676. doi: 10.2147/IJN.S406415. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37223276 Free PMC article. Review.

11

Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.

Cani M, Napoli VM, Garbo E, Ferrari G, Del Rio B, Novello S, Passiglia F. Cani M, et al. Int J Mol Sci. 2023 May 17;24(10):8883. doi: 10.3390/ijms24108883. Int J Mol Sci. 2023. PMID: 37240229 Free PMC article. Review.

12

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.

Pretelli G, Spagnolo CC, Ciappina G, Santarpia M, Pasello G. Pretelli G, et al. Int J Mol Sci. 2023 May 17;24(10):8878. doi: 10.3390/ijms24108878. Int J Mol Sci. 2023. PMID: 37240224 Free PMC article. Review.

13

Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review.

Chen Z, Jiang J, Fan Y, Lu H. Chen Z, et al. Diagn Pathol. 2023 May 17;18(1):65. doi: 10.1186/s13000-023-01354-4. Diagn Pathol. 2023. PMID: 37198615 Free PMC article. Review.

14

Small Cell Lung Cancer Treatment (PDQ®): Patient Version.

PDQ Adult Treatment Editorial Board. PDQ Adult Treatment Editorial Board. 2023 May 17. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. 2023 May 17. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389478 Free Books & Documents. Review.

15

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Corti C, Crimini E, Passaro A, de Marinis F. Spitaleri G, et al. Curr Oncol. 2023 May 16;30(5):5072-5092. doi: 10.3390/curroncol30050384. Curr Oncol. 2023. PMID: 37232842 Free PMC article. Review.

16

Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer.

Li S, Li Y, Liu Y, Wu Y, Wang Q, Jin L, Zhang D. Li S, et al. Int J Mol Sci. 2023 May 12;24(10):8642. doi: 10.3390/ijms24108642. Int J Mol Sci. 2023. PMID: 37239989 Free PMC article. Review.

17

Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer.

Gandhi S, Roy I. Gandhi S, et al. Pharmaceutics. 2023 May 10;15(5):1457. doi: 10.3390/pharmaceutics15051457. Pharmaceutics. 2023. PMID: 37242697 Free PMC article. Review.

18

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.

Novello S, Califano R, Reinmuth N, Tamma A, Puri T. Novello S, et al. Oncologist. 2023 May 8;28(5):402-413. doi: 10.1093/oncolo/oyac264. Oncologist. 2023. PMID: 36821595 Free PMC article. Review.

19

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.

Wang BC, Fu C, Lin GH. Wang BC, et al. Front Immunol. 2023 May 5;14:1185577. doi: 10.3389/fimmu.2023.1185577. eCollection 2023. Front Immunol. 2023. PMID: 37215120 Free PMC article.

20

Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis.

Zhang Y, Lu L, Zheng R. Zhang Y, et al. Front Pharmacol. 2023 May 4;14:1140771. doi: 10.3389/fphar.2023.1140771. eCollection 2023. Front Pharmacol. 2023. PMID: 37214445 Free PMC article. Review.

21

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review.

Mallio CA, Bernetti C, Cea L, Buoso A, Stiffi M, Vertulli D, Greco F, Zobel BB. Mallio CA, et al. Curr Oncol. 2023 May 3;30(5):4700-4723. doi: 10.3390/curroncol30050355. Curr Oncol. 2023. PMID: 37232813 Free PMC article. Review.

22

Improving the Understanding and Managing of the Quality of Life of Patients With Lung Cancer With Electronic Patient-Reported Outcome Measures: Scoping Review.

García Abejas A, Serra Trullás A, Sobral MA, Canelas D, Leite Costa F, Salvador Verges À. García Abejas A, et al. J Med Internet Res. 2023 May 3;25:e46259. doi: 10.2196/46259. J Med Internet Res. 2023. PMID: 37021695 Free article. Review.

23

Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.

Fernandez-Cuesta L, Sexton-Oates A, Bayat L, Foll M, Lau SCM, Leal T. Fernandez-Cuesta L, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e390794. doi: 10.1200/EDBK_390794. Am Soc Clin Oncol Educ Book. 2023. PMID: 37229617 Free article. Review.

24

Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More?

O'Reilly D, Botticella A, Barry S, Cotter S, Donington JS, Le Pechoux C, Naidoo J. O'Reilly D, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e389950. doi: 10.1200/EDBK_389950. Am Soc Clin Oncol Educ Book. 2023. PMID: 37220324 Free article. Review.

25

Biomarkers for immunotherapy in esophageal cancer.

Wang X, Wang P, Huang X, Han Y, Zhang P. Wang X, et al. Front Immunol. 2023 May 1;14:1117523. doi: 10.3389/fimmu.2023.1117523. eCollection 2023. Front Immunol. 2023. PMID: 37197663 Free PMC article. Review.

26

Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.

McNamee N, da Silva IP, Nagrial A, Gao B. McNamee N, et al. Int J Mol Sci. 2023 May 1;24(9):8129. doi: 10.3390/ijms24098129. Int J Mol Sci. 2023. PMID: 37175833 Free PMC article. Review.

27

Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.

Rosner S, Valdivia A, Hoe HJ, Murray JC, Levy B, Felip E, Solomon BJ. Rosner S, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e389968. doi: 10.1200/EDBK_389968. Am Soc Clin Oncol Educ Book. 2023. PMID: 37163707 Free article. Review.

28

Targeting neddylation as a novel approach to lung cancer treatment (Review).

Tian Z, Li J, Ma R, Li T, Sun Z, Huang S. Tian Z, et al. Int J Oncol. 2023 May;62(5):65. doi: 10.3892/ijo.2023.5513. Epub 2023 Apr 21. Int J Oncol. 2023. PMID: 37083098 Free PMC article. Review.

29

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.

Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR. Hanvesakul R, et al. J Comp Eff Res. 2023 May;12(5):e220098. doi: 10.57264/cer-2022-0098. Epub 2023 Apr 20. J Comp Eff Res. 2023. PMID: 37079341 Free article.

30

Immunotherapy-based combinations in metastatic NSCLC.

Desai A, Peters S. Desai A, et al. Cancer Treat Rev. 2023 May;116:102545. doi: 10.1016/j.ctrv.2023.102545. Epub 2023 Mar 27. Cancer Treat Rev. 2023. PMID: 37030062 Free article. Review.

31

Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.

Meng Y, Bai R, Cui J. Meng Y, et al. Thorac Cancer. 2023 May;14(13):1121-1134. doi: 10.1111/1759-7714.14858. Epub 2023 Apr 2. Thorac Cancer. 2023. PMID: 37005552 Free PMC article. Review.

32

Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.

Sun A, Abdulkarim B, Blais N, Greenland J, Louie AV, Melosky B, Schellenberg D, Snow S, Liu G. Sun A, et al. Lung Cancer. 2023 May;179:107166. doi: 10.1016/j.lungcan.2023.03.002. Epub 2023 Mar 9. Lung Cancer. 2023. PMID: 36944282 Free article. Review.

33

Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective.

Pasello G, Scattolin D, Bonanno L, Caumo F, Dell'Amore A, Scagliori E, Tinè M, Calabrese F, Benati G, Sepulcri M, Baiocchi C, Milella M, Rea F, Guarneri V. Pasello G, et al. Cancer Treat Rev. 2023 May;116:102544. doi: 10.1016/j.ctrv.2023.102544. Epub 2023 Mar 17. Cancer Treat Rev. 2023. PMID: 36940657 Free article. Review.

34

Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review.

Bernabé-Caro R, Chen Y, Dowlati A, Eason P. Bernabé-Caro R, et al. Clin Lung Cancer. 2023 May;24(3):185-208. doi: 10.1016/j.cllc.2023.01.012. Epub 2023 Feb 8. Clin Lung Cancer. 2023. PMID: 36907793 Free article. Review.

35

Evidence base for exercise prehabilitation suggests favourable outcomes for patients undergoing surgery for non-small cell lung cancer despite being of low therapeutic quality: a systematic review and meta-analysis.

Voorn MJJ, Franssen RFW, Hoogeboom TJ, van Kampen-van den Boogaart VEM, Bootsma GP, Bongers BC, Janssen-Heijnen MLG. Voorn MJJ, et al. Eur J Surg Oncol. 2023 May;49(5):879-894. doi: 10.1016/j.ejso.2023.01.024. Epub 2023 Feb 4. Eur J Surg Oncol. 2023. PMID: 36788040 Free article. Review.

36

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.

Széles Á, Fazekas T, Váncsa S, Váradi M, Kovács PT, Krafft U, Grünwald V, Hadaschik B, Csizmarik A, Hegyi P, Váradi A, Nyirády P, Szarvas T. Széles Á, et al. Cancer Immunol Immunother. 2023 May;72(5):1061-1073. doi: 10.1007/s00262-022-03328-9. Epub 2022 Nov 16. Cancer Immunol Immunother. 2023. PMID: 36385210 Free PMC article. Review.

37

A Bibliometric and In Silico-Based Analysis of Anti-Lung Cancer Compounds from Sea Cucumber.

Zare A, Izanloo S, Khaledi S, Maratovich MN, Kaliyev AA, Abenova NA, Rahmanifar F, Mahdipour M, Bakhshalizadeh S, Shirazi R, Tanideh N, Tamadon A. Zare A, et al. Mar Drugs. 2023 Apr 28;21(5):283. doi: 10.3390/md21050283. Mar Drugs. 2023. PMID: 37233477 Free PMC article. Review.

38

Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.

Lim JU, Lee E, Lee SY, Cho HJ, Ahn DH, Hwang Y, Choi JY, Yeo CD, Park CK, Kim SJ. Lim JU, et al. Transl Lung Cancer Res. 2023 Apr 28;12(4):857-876. doi: 10.21037/tlcr-22-633. Epub 2023 Mar 17. Transl Lung Cancer Res. 2023. PMID: 37197639 Free PMC article. Review.

39

Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review.

Chen J, Xu C, Lv J, Lu W, Zhang Y, Wang D, Song Y. Chen J, et al. Transl Lung Cancer Res. 2023 Apr 28;12(4):895-908. doi: 10.21037/tlcr-22-566. Epub 2023 Apr 3. Transl Lung Cancer Res. 2023. PMID: 37197619 Free PMC article. Review.

40

Promising immunotherapeutic targets in lung cancer based on single-cell RNA sequencing.

Xue Q, Peng W, Zhang S, Wei X, Ye L, Wang Z, Xiang X, Zhang P, Zhou Q. Xue Q, et al. Front Immunol. 2023 Apr 28;14:1148061. doi: 10.3389/fimmu.2023.1148061. eCollection 2023. Front Immunol. 2023. PMID: 37187731 Free PMC article. Review.

41

The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.

Peng L, Xu Q, Yin S, Zhang Y, Wu H, Liu Y, Chen L, Hu Y, Yuan J, Peng K, Lin Q. Peng L, et al. Front Oncol. 2023 Apr 27;13:1153319. doi: 10.3389/fonc.2023.1153319. eCollection 2023. Front Oncol. 2023. PMID: 37182180 Free PMC article. Review.

42

EB-OCT: a potential strategy on early diagnosis and treatment for lung cancer.

Long H, Ji J, Chen L, Feng J, Liao J, Yang Y. Long H, et al. Front Oncol. 2023 Apr 25;13:1156218. doi: 10.3389/fonc.2023.1156218. eCollection 2023. Front Oncol. 2023. PMID: 37182131 Free PMC article. Review.

43

Biomarkers in the management of lung cancer: changing the practice of thoracic oncology.

Melichar B. Melichar B. Clin Chem Lab Med. 2022 Nov 16;61(5):906-920. doi: 10.1515/cclm-2022-1108. Print 2023 Apr 25. Clin Chem Lab Med. 2022. PMID: 36384005 Free article. Review.

44

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.

Ge Y, Ye T, Fu S, Jiang X, Song H, Liu B, Wang G, Wang J. Ge Y, et al. Front Immunol. 2023 Apr 21;14:1114041. doi: 10.3389/fimmu.2023.1114041. eCollection 2023. Front Immunol. 2023. PMID: 37153619 Free PMC article. Review.

45

Evaluation of surgical outcomes and prognostic factors of second primary lung cancer based on a systematic review and meta-analysis.

Zhao J, Shen Z, Huang Y, Zhao G, Wang W, Yang Y, Zhou C, Ye L. Zhao J, et al. BMC Surg. 2023 Apr 21;23(1):95. doi: 10.1186/s12893-023-02003-9. BMC Surg. 2023. PMID: 37085804 Free PMC article.

46

Transcutaneous electronic acupoint stimulation improves bone marrow suppression in lung cancer patients following chemotherapy: A systematic review and meta-analysis of randomized controlled trials.

Wei Y, Zheng Y. Wei Y, et al. Medicine (Baltimore). 2023 Apr 21;102(16):e33571. doi: 10.1097/MD.0000000000033571. Medicine (Baltimore). 2023. PMID: 37083807 Free PMC article.

47

'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.

Verma S, Breadner D, Raphael J. Verma S, et al. Curr Oncol. 2023 Apr 20;30(4):4329-4350. doi: 10.3390/curroncol30040330. Curr Oncol. 2023. PMID: 37185443 Free PMC article. Review.

48

Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions.

Zoń A, Bednarek I. Zoń A, et al. Int J Mol Sci. 2023 Apr 20;24(8):7585. doi: 10.3390/ijms24087585. Int J Mol Sci. 2023. PMID: 37108749 Free PMC article. Review.

49

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.

Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E, Beau-Faller M, Mascaux C. Pabst L, et al. Int J Mol Sci. 2023 Apr 20;24(8):7577. doi: 10.3390/ijms24087577. Int J Mol Sci. 2023. PMID: 37108738 Free PMC article. Review.

50

Epigenetic regulation of stem cells in lung cancer oncogenesis and therapy resistance.

Wu J, Feng J, Zhang Q, He Y, Xu C, Wang C, Li W. Wu J, et al. Front Genet. 2023 Apr 18;14:1120815. doi: 10.3389/fgene.2023.1120815. eCollection 2023. Front Genet. 2023. PMID: 37144123 Free PMC article. Review.

51

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.

Liu T, Wu S, Fang W, Li H, Su L, Qi G, Li H, Liu Y. Liu T, et al. PLoS One. 2023 Apr 18;18(4):e0283719. doi: 10.1371/journal.pone.0283719. eCollection 2023. PLoS One. 2023. PMID: 37071610 Free PMC article.

52

Emerging evidence and treatment paradigm of non-small cell lung cancer.

Liu SM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL. Liu SM, et al. J Hematol Oncol. 2023 Apr 17;16(1):40. doi: 10.1186/s13045-023-01436-2. J Hematol Oncol. 2023. PMID: 37069698 Free PMC article. Review.

53

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.

Leone GM, Candido S, Lavoro A, Vivarelli S, Gattuso G, Calina D, Libra M, Falzone L. Leone GM, et al. Pharmaceutics. 2023 Apr 16;15(4):1252. doi: 10.3390/pharmaceutics15041252. Pharmaceutics. 2023. PMID: 37111737 Free PMC article. Review.

54

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer.

Spagnuolo A, Gridelli C. Spagnuolo A, et al. Cancers (Basel). 2023 Apr 15;15(8):2319. doi: 10.3390/cancers15082319. Cancers (Basel). 2023. PMID: 37190247 Free PMC article. Review.

55

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer.

Rao DY, Huang DF, Si MY, Lu H, Tang ZX, Zhang ZX. Rao DY, et al. Front Immunol. 2023 Apr 12;14:1142539. doi: 10.3389/fimmu.2023.1142539. eCollection 2023. Front Immunol. 2023. PMID: 37122754 Free PMC article. Review.

56

Innovative Invasive Loco-Regional Techniques for the Treatment of Lung Cancer.

Claes E, Wener R, Neyrinck AP, Coppens A, Van Schil PE, Janssens A, Lapperre TS, Snoeckx A, Wen W, Voet H, Verleden SE, Hendriks JMH. Claes E, et al. Cancers (Basel). 2023 Apr 11;15(8):2244. doi: 10.3390/cancers15082244. Cancers (Basel). 2023. PMID: 37190172 Free PMC article. Review.

57

Association of lung-intestinal microecology and lung cancer therapy.

Kong LY, Chen XY, Lu X, Caiyin Q, Yang DH. Kong LY, et al. Chin Med. 2023 Apr 10;18(1):37. doi: 10.1186/s13020-023-00742-8. Chin Med. 2023. PMID: 37038223 Free PMC article. Review.

58

Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions.

O'Sullivan HM, Feber A, Popat S. O'Sullivan HM, et al. Onco Targets Ther. 2023 Apr 7;16:249-259. doi: 10.2147/OTT.S322242. eCollection 2023. Onco Targets Ther. 2023. PMID: 37056631 Free PMC article. Review.

59

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.

Zhou S, Yang H. Zhou S, et al. Front Immunol. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465. eCollection 2023. Front Immunol. 2023. PMID: 37090727 Free PMC article. Review.

60

Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.

Zhang J, Johnson M, Barve M, Bazhenova L, McCarthy M, Schwartz R, Horvath-Walsh E, Velastegui K, Qian C, Spira A. Zhang J, et al. Oncologist. 2023 Apr 6;28(4):287-296. doi: 10.1093/oncolo/oyad051. Oncologist. 2023. PMID: 36892150 Free PMC article. Review.

61

Guo X, Chen S, Wang X, Liu X. Guo X, et al. Front Immunol. 2023 Apr 4;14:1138483. doi: 10.3389/fimmu.2023.1138483. eCollection 2023. Front Immunol. 2023. PMID: 37081866 Free PMC article. Review.

62

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review.

Xiong W, Guo X, Du H, Xu M, Zhao Y. Xiong W, et al. BMJ Open Respir Res. 2023 Apr;10(1):e001493. doi: 10.1136/bmjresp-2022-001493. BMJ Open Respir Res. 2023. PMID: 37068846 Free PMC article. Review.

63

Ferroptosis in lung cancer: a novel pathway regulating cell death and a promising target for drug therapy.

Xing N, Du Q, Guo S, Xiang G, Zhang Y, Meng X, Xiang L, Wang S. Xing N, et al. Cell Death Discov. 2023 Apr 1;9(1):110. doi: 10.1038/s41420-023-01407-z. Cell Death Discov. 2023. PMID: 37005430 Free PMC article. Review.

64

Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).

Gridelli C, Peters S, Velcheti V, Attili I, de Marinis F. Gridelli C, et al. ESMO Open. 2023 Apr;8(2):101192. doi: 10.1016/j.esmoop.2023.101192. Epub 2023 Mar 23. ESMO Open. 2023. PMID: 36965261 Free PMC article. Review.

65

Anti-TIGIT therapies for solid tumors: a systematic review.

Rousseau A, Parisi C, Barlesi F. Rousseau A, et al. ESMO Open. 2023 Apr;8(2):101184. doi: 10.1016/j.esmoop.2023.101184. Epub 2023 Mar 16. ESMO Open. 2023. PMID: 36933320 Free PMC article. Review.

66

Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer.

Cui Y, Zhao P, Cheng Y, Ren X. Cui Y, et al. Thorac Cancer. 2023 Apr;14(10):864-872. doi: 10.1111/1759-7714.14837. Epub 2023 Mar 1. Thorac Cancer. 2023. PMID: 36861174 Free PMC article. Review.

67

Education messages and strategies to inform the public, potential screening candidates and healthcare providers about lung cancer screening: A systematic review.

Dodd RH, Sharman AR, McGregor D, Stone E, Donnelly C, Lourenco RA, Marshall H, Rankin NM. Dodd RH, et al. Prev Med. 2023 Apr;169:107459. doi: 10.1016/j.ypmed.2023.107459. Epub 2023 Feb 26. Prev Med. 2023. PMID: 36854365 Free article. Review.

68

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.

Gouda MA, Subbiah V. Gouda MA, et al. ESMO Open. 2023 Apr;8(2):100788. doi: 10.1016/j.esmoop.2023.100788. Epub 2023 Feb 24. ESMO Open. 2023. PMID: 36842301 Free PMC article. Review.

69

Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F, Berruti A. Amoroso V, et al. ESMO Open. 2023 Apr;8(2):100787. doi: 10.1016/j.esmoop.2023.100787. Epub 2023 Feb 24. ESMO Open. 2023. PMID: 36842300 Free PMC article. Review.

70

Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.

Kifjak D, Hochmair MJ, Krenbek D, Milos RI, Heidinger BH, Prayer F, Röhrich S, Watzenboeck ML, Oberndorfer F, Klikovits T, Aigner C, Sinn K, Hoda MA, Hoetzenecker K, Haug AR, Prosch H, Beer L. Kifjak D, et al. Eur J Radiol. 2023 Apr;161:110732. doi: 10.1016/j.ejrad.2023.110732. Epub 2023 Feb 8. Eur J Radiol. 2023. PMID: 36804313 Free article. Review.

71

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Al Khayat MNMT, Armstrong N, Howick J, O'Meara S, Posadzki P, Ryder S, Ahmadu C, Konings SRA, Postma MJ, Duffy S, Wolff RF, van Asselt ADI. Al Khayat MNMT, et al. Pharmacoeconomics. 2023 Apr;41(4):353-361. doi: 10.1007/s40273-023-01247-w. Epub 2023 Feb 9. Pharmacoeconomics. 2023. PMID: 36757608 Free PMC article. Review.

72

The pharmacological and biological importance of EZH2 signaling in lung cancer.

Entezari M, Taheriazam A, Paskeh MDA, Sabouni E, Zandieh MA, Aboutalebi M, Kakavand A, Rezaei S, Hejazi ES, Saebfar H, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. Entezari M, et al. Biomed Pharmacother. 2023 Apr;160:114313. doi: 10.1016/j.biopha.2023.114313. Epub 2023 Feb 3. Biomed Pharmacother. 2023. PMID: 36738498 Free article. Review.

73

Carcinoid tumors outside the abdomen.

Koehler K, Iams WT. Koehler K, et al. Cancer Med. 2023 Apr;12(7):7893-7903. doi: 10.1002/cam4.5564. Epub 2022 Dec 22. Cancer Med. 2023. PMID: 36560885 Free PMC article. Review.

74

Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.

Yang Y, Liu H, Chen Y, Xiao N, Zheng Z, Liu H, Wan J. Yang Y, et al. Cell Death Dis. 2023 Mar 31;14(3):230. doi: 10.1038/s41419-023-05757-5. Cell Death Dis. 2023. PMID: 37002211 Free PMC article. Review.

75

Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours.

Dumoulin DW, Bironzo P, Passiglia F, Scagliotti GV, Aerts JGJV; ERN-LUNG Core Network Mesothelioma. Dumoulin DW, et al. Eur Respir Rev. 2023 Feb 7;32(167):220174. doi: 10.1183/16000617.0174-2022. Print 2023 Mar 31. Eur Respir Rev. 2023. PMID: 36754434 Free PMC article. Review.

76

Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial.

Ko JJ, Banerji S, Blais N, Brade A, Clelland C, Schellenberg D, Snow S, Wheatley-Price P, Yuan R, Melosky B. Ko JJ, et al. Curr Oncol. 2023 Mar 29;30(4):3817-3828. doi: 10.3390/curroncol30040289. Curr Oncol. 2023. PMID: 37185402 Free PMC article. Review.

77

Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.

Lazzari C, Spagnolo CC, Ciappina G, Di Pietro M, Squeri A, Passalacqua MI, Marchesi S, Gregorc V, Santarpia M. Lazzari C, et al. Curr Oncol. 2023 Mar 27;30(4):3684-3696. doi: 10.3390/curroncol30040280. Curr Oncol. 2023. PMID: 37185393 Free PMC article. Review.

78

The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses.

Ciccone G, Ibba ML, Coppola G, Catuogno S, Esposito CL. Ciccone G, et al. Int J Mol Sci. 2023 Mar 24;24(7):6121. doi: 10.3390/ijms24076121. Int J Mol Sci. 2023. PMID: 37047090 Free PMC article. Review.

79

Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.

Kowash RR, Akbay EA. Kowash RR, et al. Front Immunol. 2023 Mar 24;14:1130358. doi: 10.3389/fimmu.2023.1130358. eCollection 2023. Front Immunol. 2023. PMID: 37033953 Free PMC article. Review.

80

Heat Shock Proteins in Non-Small-Cell Lung Cancer-Functional Mechanism.

Zhou G, Pu Y, Zhao K, Chen Y, Zhang G. Zhou G, et al. Front Biosci (Landmark Ed). 2023 Mar 20;28(3):56. doi: 10.31083/j.fbl2803056. Front Biosci (Landmark Ed). 2023. PMID: 37005758 Free article. Review.

81

Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review.

Król K, Mazur A, Stachyra-Strawa P, Grzybowska-Szatkowska L. Król K, et al. Int J Mol Sci. 2023 Mar 20;24(6):5858. doi: 10.3390/ijms24065858. Int J Mol Sci. 2023. PMID: 36982933 Free PMC article. Review.

82

Plain language summary and patient perspective of the European Society for Medical Oncology expert consensus statements on treating EGFR-positive non-small-cell lung cancer.

Jenkins R, Walker J, Roy UB. Jenkins R, et al. Future Oncol. 2023 Mar 20. doi: 10.2217/fon-2022-1213. Online ahead of print. Future Oncol. 2023. PMID: 36935637 Free article. Review.

83

Theranostic applications of selenium nanomedicines against lung cancer.

Liu S, Wei W, Wang J, Chen T. Liu S, et al. J Nanobiotechnology. 2023 Mar 20;21(1):96. doi: 10.1186/s12951-023-01825-2. J Nanobiotechnology. 2023. PMID: 36935493 Free PMC article. Review.

84

Diet as a Factor Supporting Lung Cancer Treatment-A Systematic Review.

Polański J, Świątoniowska-Lonc N, Kołaczyńska S, Chabowski M. Polański J, et al. Nutrients. 2023 Mar 19;15(6):1477. doi: 10.3390/nu15061477. Nutrients. 2023. PMID: 36986207 Free PMC article. Review.

85

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.

Cheon SY, Kwon S. Cheon SY, et al. Int J Mol Sci. 2023 Mar 18;24(6):5821. doi: 10.3390/ijms24065821. Int J Mol Sci. 2023. PMID: 36982897 Free PMC article. Review.

86

Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.

Yu S, Zhang S, Xu H, Yang G, Xu F, Yang L, Chen D, An G, Wang Y. Yu S, et al. BMJ Open. 2023 Mar 17;13(3):e059457. doi: 10.1136/bmjopen-2021-059457. BMJ Open. 2023. PMID: 36931679 Free PMC article.

87

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis.

Shi H, Guo N, Zhao Z, Liu L, Ni T, Zhang J, Lu Y. Shi H, et al. Front Oncol. 2023 Mar 16;13:1154685. doi: 10.3389/fonc.2023.1154685. eCollection 2023. Front Oncol. 2023. PMID: 37007093 Free PMC article.

88

Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors.

Vaseq R, Sharma A, Li Y, Schmidt-Wolf IGH. Vaseq R, et al. Int J Mol Sci. 2023 Mar 15;24(6):5626. doi: 10.3390/ijms24065626. Int J Mol Sci. 2023. PMID: 36982701 Free PMC article. Review.

89

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives.

Sulewska A, Pilz L, Manegold C, Ramlau R, Charkiewicz R, Niklinski J. Sulewska A, et al. Cells. 2023 Mar 15;12(6):905. doi: 10.3390/cells12060905. Cells. 2023. PMID: 36980246 Free PMC article. Review.

90

Research Priorities for Interventions to Address Health Disparities in Lung Nodule Management: An Official American Thoracic Society Research Statement.

Steiling K, Kathuria H, Echieh CP, Ost DE, Rivera MP, Begnaud A, Celedón JC, Charlot M, Dietrick F, Duma N, Fong KM, Ford JG, Gould MK, Holguin F, Pérez-Stable EJ, Tanner NT, Thomson CC, Wiener RS, Wisnivesky J. Steiling K, et al. Am J Respir Crit Care Med. 2023 Mar 15;207(6):e31-e46. doi: 10.1164/rccm.202212-2216ST. Am J Respir Crit Care Med. 2023. PMID: 36920066 Free PMC article.

91

RET signaling in breast cancer therapeutic resistance and metastasis.

Pecar G, Liu S, Hooda J, Atkinson JM, Oesterreich S, Lee AV. Pecar G, et al. Breast Cancer Res. 2023 Mar 14;25(1):26. doi: 10.1186/s13058-023-01622-7. Breast Cancer Res. 2023. PMID: 36918928 Free PMC article. Review.

92

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis.

Wu J, Ni T, Deng R, Li Y, Zhong Q, Tang F, Zhang Q, Fang C, Xue Y, Zha Y, Zhang Y. Wu J, et al. Front Immunol. 2023 Mar 13;14:1065510. doi: 10.3389/fimmu.2023.1065510. eCollection 2023. Front Immunol. 2023. PMID: 36993952 Free PMC article.

93

Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses.

Mortezaee K, Majidpoor J. Mortezaee K, et al. Heliyon. 2023 Mar 13;9(3):e14566. doi: 10.1016/j.heliyon.2023.e14566. eCollection 2023 Mar. Heliyon. 2023. PMID: 36950599 Free PMC article. Review.

94

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment.

Zaim R, Redekop WK, Uyl-de Groot CA. Zaim R, et al. Front Health Serv. 2023 Mar 13;3:1034256. doi: 10.3389/frhs.2023.1034256. eCollection 2023. Front Health Serv. 2023. PMID: 36926505 Free PMC article. Review.

95

Non-pharmacological interventions on anxiety and depression in lung cancer patients' informal caregivers: A systematic review and meta-analysis.

Lei F, Lee E, Shin J, Lee SY. Lei F, et al. PLoS One. 2023 Mar 13;18(3):e0282887. doi: 10.1371/journal.pone.0282887. eCollection 2023. PLoS One. 2023. PMID: 36913399 Free PMC article.

96

Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer.

Yang YC, Zhao CJ, Jin ZF, Zheng J, Ma LT. Yang YC, et al. Front Oncol. 2023 Mar 9;13:1120828. doi: 10.3389/fonc.2023.1120828. eCollection 2023. Front Oncol. 2023. PMID: 36969062 Free PMC article. Review.

97

Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review.

Li CC, Lin YC, Liang JA, Chao KSC, Hsia TC, Chien CR. Li CC, et al. Int J Environ Res Public Health. 2023 Mar 7;20(6):4727. doi: 10.3390/ijerph20064727. Int J Environ Res Public Health. 2023. PMID: 36981635 Free PMC article. Review.

98

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.

O'Sullivan É, Keogh A, Henderson B, Finn SP, Gray SG, Gately K. O'Sullivan É, et al. Cancers (Basel). 2023 Mar 7;15(6):1635. doi: 10.3390/cancers15061635. Cancers (Basel). 2023. PMID: 36980522 Free PMC article. Review.

99

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.

Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, Bonomo L, Del Grande F, Casiraghi M, De Marinis F, Spaggiari L. Petrella F, et al. Curr Oncol. 2023 Mar 7;30(3):3160-3175. doi: 10.3390/curroncol30030239. Curr Oncol. 2023. PMID: 36975452 Free PMC article. Review.

100

Advances in immune checkpoint inhibitors therapy for small cell lung cancer.

Li L, Liang Y, Yu M, Zhao L, Mei Q, Yu Y, Wang N, Zhang D, Wang Z, Jia Y, Kong F. Li L, et al. Cancer Med. 2023 Mar 7. doi: 10.1002/cam4.5659. Online ahead of print. Cancer Med. 2023. PMID: 36880420 Free article. Review.

101

Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments.

Chen S, Tang J, Liu F, Li W, Yan T, Shangguan D, Yang N, Liao D. Chen S, et al. Front Immunol. 2023 Mar 6;14:1094764. doi: 10.3389/fimmu.2023.1094764. eCollection 2023. Front Immunol. 2023. PMID: 36949948 Free PMC article. Review.

102

Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.

Wang TF, Carrier M. Wang TF, et al. Curr Oncol. 2023 Mar 4;30(3):3032-3046. doi: 10.3390/curroncol30030230. Curr Oncol. 2023. PMID: 36975443 Free PMC article. Review.

103

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer.

Moonmuang S, Tantraworasin A, Orrapin S, Udomruk S, Chewaskulyong B, Pruksakorn D, Chaiyawat P. Moonmuang S, et al. Int J Mol Sci. 2023 Mar 2;24(5):4827. doi: 10.3390/ijms24054827. Int J Mol Sci. 2023. PMID: 36902280 Free PMC article. Review.

104

Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version.

PDQ Adult Treatment Editorial Board. PDQ Adult Treatment Editorial Board. 2023 Mar 2. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. 2023 Mar 2. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389347 Free Books & Documents. Review.

105

Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.

Hallick J, Baird AM, Falchook G, Le X, Hong D, Viteri S, Raskin J, Reinmuth N, Vlassak S, Militaru M, Paik PK. Hallick J, et al. Future Oncol. 2023 Mar;19(10):683-696. doi: 10.2217/fon-2022-1035. Epub 2023 Mar 31. Future Oncol. 2023. PMID: 36999526 Free article. Review.

106

Therapeutic Strategies and Oncological Outcome of Peritoneal Metastases from Lung Cancer: A Systematic Review and Pooled Analysis.

Siragusa L, Di Carlo S, Fassari A, Sensi B, Riccetti C, Izzo L, Cavallaro G, Fiori E, Sapienza P, Mallia L, Pernazza G, Sibio S. Siragusa L, et al. Curr Oncol. 2023 Mar 1;30(3):2928-2941. doi: 10.3390/curroncol30030224. Curr Oncol. 2023. PMID: 36975437 Free PMC article. Review.

107

Clinicopathological features and prognosis of primary pulmonary rhabdomyosarcoma in middle-aged and elderly patients: a case report and literature review.

Xiaoxia J, Guihua Z, Jiatai W, Xinghua Z, Xudong C, Yingze W. Xiaoxia J, et al. J Int Med Res. 2023 Mar;51(3):3000605231159782. doi: 10.1177/03000605231159782. J Int Med Res. 2023. PMID: 36883437 Free PMC article. Review.

108

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Forde PM, et al. Future Oncol. 2023 Mar;19(8):549-557. doi: 10.2217/fon-2023-0007. Epub 2023 Feb 23. Future Oncol. 2023. PMID: 36815433 Free article. Review.

109

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.

Nardone V, Romeo C, D'Ippolito E, Pastina P, D'Apolito M, Pirtoli L, Caraglia M, Mutti L, Bianco G, Falzea AC, Giannicola R, Giordano A, Tagliaferri P, Vinciguerra C, Desideri I, Loi M, Reginelli A, Cappabianca S, Tassone P, Correale P. Nardone V, et al. Radiol Med. 2023 Mar;128(3):316-329. doi: 10.1007/s11547-023-01602-z. Epub 2023 Feb 14. Radiol Med. 2023. PMID: 36786970 Free PMC article. Review.

110

Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.

Yu Y, Yang Y, Li H, Fan Y. Yu Y, et al. Cancer Treat Rev. 2023 Mar;114:102520. doi: 10.1016/j.ctrv.2023.102520. Epub 2023 Jan 27. Cancer Treat Rev. 2023. PMID: 36738637 Free article. Review.

111

Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.

Blakely CM, Weder W, Bubendorf L, He J, Majem M, Shyr Y, Chaft JE. Blakely CM, et al. Lung Cancer. 2023 Mar;177:59-72. doi: 10.1016/j.lungcan.2023.01.002. Epub 2023 Jan 2. Lung Cancer. 2023. PMID: 36736076 Free article. Review.

112

Old age and EGFR mutation status in inoperable early-stage non-small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan.

Wu YH, Kang YM, Hu YW, Lan KL, Yen SH, Lai TY, Lan TL, Chen YM, Chiu CH, Luo YH, Chao HS, Chiang CL, Shiao TH, Yang CN, Hsu WH, Wu YC, Hsu HS, Hung JJ, Huang CS, Hsu PK, Chen YW. Wu YH, et al. Thorac Cancer. 2023 Mar;14(7):654-661. doi: 10.1111/1759-7714.14786. Epub 2023 Jan 18. Thorac Cancer. 2023. PMID: 36653333 Free PMC article. Review.

113

Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.

Zhang H, Yang Y, Li X, Yuan X, Chu Q. Zhang H, et al. Biomed Pharmacother. 2023 Mar;159:114248. doi: 10.1016/j.biopha.2023.114248. Epub 2023 Jan 14. Biomed Pharmacother. 2023. PMID: 36645960 Free article. Review.

114

Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers.

van Kooten JP, de Gooijer CJ, von der Thüsen JH, Brandt-Kerkhof ARM, Albers AGJ, Lahaye MJ, Monkhorst K, Burgers JA, Aerts JGJV, Verhoef C, Madsen EVE. van Kooten JP, et al. Eur J Surg Oncol. 2023 Mar;49(3):611-618. doi: 10.1016/j.ejso.2022.10.003. Epub 2022 Oct 27. Eur J Surg Oncol. 2023. PMID: 36610896 Free article. Review.

115

Computed Tomography Features and Tumor Spread Through Air Spaces in Lung Adenocarcinoma: A Meta-analysis.

Gu Y, Zheng B, Zhao T, Fan Y. Gu Y, et al. J Thorac Imaging. 2023 Mar 1;38(2):W19-W29. doi: 10.1097/RTI.0000000000000693. Epub 2022 Dec 28. J Thorac Imaging. 2023. PMID: 36583661 Free PMC article.

116

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.

Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Cho BC, et al. Clin Lung Cancer. 2023 Mar;24(2):89-97. doi: 10.1016/j.cllc.2022.11.004. Epub 2022 Nov 11. Clin Lung Cancer. 2023. PMID: 36481319 Free article. Review.

117

PROTAC therapy as a new targeted therapy for lung cancer.

Li JW, Zheng G, Kaye FJ, Wu L. Li JW, et al. Mol Ther. 2023 Mar 1;31(3):647-656. doi: 10.1016/j.ymthe.2022.11.011. Epub 2022 Nov 22. Mol Ther. 2023. PMID: 36415148 Free article. Review.

118

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.

Chen W, Zhang L, Shen H, Wang B, Luo J, Cui E. Chen W, et al. Anticancer Drugs. 2023 Mar 1;34(3):460-466. doi: 10.1097/CAD.0000000000001436. Epub 2022 Nov 14. Anticancer Drugs. 2023. PMID: 36373747 Free PMC article. Review.

119

Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.

Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Yu L, et al. Cancer Med. 2023 Mar;12(5):5372-5383. doi: 10.1002/cam4.5360. Epub 2022 Oct 17. Cancer Med. 2023. PMID: 36250532 Free PMC article. Review.

120

The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update.

Lotfi N, Yousefi Z, Golabi M, Khalilian P, Ghezelbash B, Montazeri M, Shams MH, Baghbadorani PZ, Eskandari N. Lotfi N, et al. Front Immunol. 2023 Feb 28;14:1077531. doi: 10.3389/fimmu.2023.1077531. eCollection 2023. Front Immunol. 2023. PMID: 36926328 Free PMC article. Review.

121

Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.

Liu H, Luo SX, Jie J, Peng L, Wang S, Song L. Liu H, et al. Front Immunol. 2023 Feb 28;14:1115305. doi: 10.3389/fimmu.2023.1115305. eCollection 2023. Front Immunol. 2023. PMID: 36926326 Free PMC article.

122

The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review.

Shinohara S, Takahashi Y, Masago K, Matsushita H, Kuroda H. Shinohara S, et al. J Thorac Dis. 2023 Feb 28;15(2):747-758. doi: 10.21037/jtd-22-957. Epub 2023 Feb 2. J Thorac Dis. 2023. PMID: 36910085 Free PMC article. Review.

123

Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review.

Chazan G, Solomon BJ. Chazan G, et al. Transl Lung Cancer Res. 2023 Feb 28;12(2):369-378. doi: 10.21037/tlcr-22-656. Epub 2023 Feb 25. Transl Lung Cancer Res. 2023. PMID: 36895924 Free PMC article. Review.

124

Pyodermitis during Nivolumab Treatment for Non-Small Cell Lung Cancer: A Case Report and Review of the Literature.

Cosio T, Coniglione F, Flaminio V, Gaziano R, Coletta D, Petruccelli R, Dika E, Bianchi L, Campione E. Cosio T, et al. Int J Mol Sci. 2023 Feb 26;24(5):4580. doi: 10.3390/ijms24054580. Int J Mol Sci. 2023. PMID: 36902013 Free PMC article. Review.

125

The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases.

Billena C, Lobbous M, Cordova CA, Peereboom D, Torres-Trejo A, Chan T, Murphy E, Chao ST, Suh J, Yu JS. Billena C, et al. Front Oncol. 2023 Feb 23;13:1110440. doi: 10.3389/fonc.2023.1110440. eCollection 2023. Front Oncol. 2023. PMID: 36910642 Free PMC article. Review.

126

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.

Zhou N, Chen Y, Huang Q, Jiang L, Liao H, Gou H, Lu Y, Che G, Zhang Y. Zhou N, et al. Front Immunol. 2023 Feb 22;14:1111325. doi: 10.3389/fimmu.2023.1111325. eCollection 2023. Front Immunol. 2023. PMID: 36911701 Free PMC article. Review.

127

Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment.

Alduais Y, Zhang H, Fan F, Chen J, Chen B. Alduais Y, et al. Medicine (Baltimore). 2023 Feb 22;102(8):e32899. doi: 10.1097/MD.0000000000032899. Medicine (Baltimore). 2023. PMID: 36827002 Free article. Review.

128

Recent progress in targeted therapy for non-small cell lung cancer.

Xiao Y, Liu P, Wei J, Zhang X, Guo J, Lin Y. Xiao Y, et al. Front Pharmacol. 2023 Feb 21;14:1125547. doi: 10.3389/fphar.2023.1125547. eCollection 2023. Front Pharmacol. 2023. PMID: 36909198 Free PMC article. Review.

129

Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines.

Shi T, Sun M, Lu C, Meng F. Shi T, et al. Front Immunol. 2023 Feb 21;14:1125253. doi: 10.3389/fimmu.2023.1125253. eCollection 2023. Front Immunol. 2023. PMID: 36895553 Free PMC article. Review.

130

Excellent survival of pathological N0 small cell lung cancer patients following surgery.

Fu Z, Li D, Deng C, Zhang J, Bai J, Li Y, Chen H, Zhang Y. Fu Z, et al. Eur J Med Res. 2023 Feb 21;28(1):91. doi: 10.1186/s40001-023-01044-3. Eur J Med Res. 2023. PMID: 36810128 Free PMC article. Review.

131

Lung cancer immunotherapy: progress, pitfalls, and promises.

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lahiri A, et al. Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y. Mol Cancer. 2023. PMID: 36810079 Free PMC article. Review.

132

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC.

Kobayashi K, Tan AC. Kobayashi K, et al. Int J Mol Sci. 2023 Feb 18;24(4):4126. doi: 10.3390/ijms24044126. Int J Mol Sci. 2023. PMID: 36835536 Free PMC article. Review.

133

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer.

Jie C, Li R, Cheng Y, Wang Z, Wu Q, Xie C. Jie C, et al. Front Immunol. 2023 Feb 17;14:1122352. doi: 10.3389/fimmu.2023.1122352. eCollection 2023. Front Immunol. 2023. PMID: 36875059 Free PMC article. Review.

134

New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination.

Fernandes MP, Oliveira C, Sousa H, Oliveira J. Fernandes MP, et al. Int J Mol Sci. 2023 Feb 17;24(4):4044. doi: 10.3390/ijms24044044. Int J Mol Sci. 2023. PMID: 36835456 Free PMC article. Review.

135

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.

Vathiotis IA, Bafaloukos D, Syrigos KN, Samonis G. Vathiotis IA, et al. Cancers (Basel). 2023 Feb 17;15(4):1286. doi: 10.3390/cancers15041286. Cancers (Basel). 2023. PMID: 36831628 Free PMC article. Review.

136

Clear cell "sugar" tumor of the lung: Diagnostic characteristics of a rare pulmonary tumor: A case report and review of literature.

Wang B, Xu X, Zhao Z. Wang B, et al. Medicine (Baltimore). 2023 Feb 17;102(7):e33035. doi: 10.1097/MD.0000000000033035. Medicine (Baltimore). 2023. PMID: 36800595 Free PMC article. Review.

137

Non-Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version.

PDQ Adult Treatment Editorial Board. PDQ Adult Treatment Editorial Board. 2023 Feb 17. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. 2023 Feb 17. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389304 Free Books & Documents. Review.

138

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.

Russano M, La Cava G, Cortellini A, Citarella F, Galletti A, Di Fazio GR, Santo V, Brunetti L, Vendittelli A, Fioroni I, Pantano F, Tonini G, Vincenzi B. Russano M, et al. Curr Oncol. 2023 Feb 16;30(2):2366-2387. doi: 10.3390/curroncol30020181. Curr Oncol. 2023. PMID: 36826142 Free PMC article. Review.

139

Non-Small Cell Lung Cancer Treatment (PDQ®): Patient Version.

PDQ Adult Treatment Editorial Board. PDQ Adult Treatment Editorial Board. 2023 Feb 16. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. 2023 Feb 16. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389355 Free Books & Documents. Review.

140

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer.

Zhou T, Zhang LY, He JZ, Miao ZM, Li YY, Zhang YM, Liu ZW, Zhang SZ, Chen Y, Zhou GC, Liu YQ. Zhou T, et al. Front Immunol. 2023 Feb 14;14:1133899. doi: 10.3389/fimmu.2023.1133899. eCollection 2023. Front Immunol. 2023. PMID: 36865554 Free PMC article. Review.

141

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.

Zhao N, Wu ZP, Yang J, Feng WN, Yang SL, Luo Y, Ye J, Wang F, Zhang XW, Xiao Y, Wu LL, Gu WQ. Zhao N, et al. World J Surg Oncol. 2023 Feb 13;21(1):45. doi: 10.1186/s12957-023-02925-x. World J Surg Oncol. 2023. PMID: 36782320 Free PMC article. Review.

142

Pulmonary sclerosing pneumocytoma containing spindle cells with sarcomatoid features: a case report with literature review.

Liang J, Du Q, Ye X, Huang W. Liang J, et al. Diagn Pathol. 2023 Feb 10;18(1):16. doi: 10.1186/s13000-023-01296-x. Diagn Pathol. 2023. PMID: 36759857 Free PMC article. Review.

143

Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature.

Yun JW, Kwon J, Lim T. Yun JW, et al. Medicina (Kaunas). 2023 Feb 9;59(2):325. doi: 10.3390/medicina59020325. Medicina (Kaunas). 2023. PMID: 36837526 Free PMC article. Review.

144

Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now?

Chan JWY, Siu ICH, Chang ATC, Li MSC, Lau RWH, Mok TSK, Ng CSH. Chan JWY, et al. Cancers (Basel). 2023 Feb 8;15(4):1068. doi: 10.3390/cancers15041068. Cancers (Basel). 2023. PMID: 36831411 Free PMC article. Review.

145

Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives.

Alshammari MK, Almomen EY, Alshahrani KF, Altwalah SF, Kamal M, Al-Twallah MF, Alsanad SH, Al-Batti MH, Al-Rasheed FJ, Alsalamah AY, Alhazza MB, Alasmari FA, Abida, Imran M. Alshammari MK, et al. Biomedicines. 2023 Feb 6;11(2):473. doi: 10.3390/biomedicines11020473. Biomedicines. 2023. PMID: 36831009 Free PMC article. Review.

146

Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer.

Czarnecka-Chrebelska KH, Mukherjee D, Maryanchik SV, Rudzinska-Radecka M. Czarnecka-Chrebelska KH, et al. Biomedicines. 2023 Feb 3;11(2):448. doi: 10.3390/biomedicines11020448. Biomedicines. 2023. PMID: 36830984 Free PMC article. Review.

147

Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary.

Yang JC. Yang JC. Future Oncol. 2023 Feb;19(4):291-297. doi: 10.2217/fon-2022-0842. Epub 2023 Feb 16. Future Oncol. 2023. PMID: 36794564 Free article. Review.

148

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review.

Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW, Amir E. Al-Showbaki L, et al. J Immunother Cancer. 2023 Feb;11(2):e005854. doi: 10.1136/jitc-2022-005854. J Immunother Cancer. 2023. PMID: 36792122 Free PMC article.

149

A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.

Aggarwal H, Ndirangu K, Winfree KB, Muehlenbein CE, Zhu E, Tongbram V, Thom H. Aggarwal H, et al. J Comp Eff Res. 2023 Feb;12(2):e220016. doi: 10.2217/cer-2022-0016. Epub 2023 Jan 9. J Comp Eff Res. 2023. PMID: 36621905 Free article. Review.

150

Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).

Wang Q, Zeng A, Zhu M, Song L. Wang Q, et al. Int J Oncol. 2023 Feb;62(2):26. doi: 10.3892/ijo.2023.5474. Epub 2023 Jan 5. Int J Oncol. 2023. PMID: 36601768 Free PMC article. Review.

151

Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.

Gristina V, La Mantia M, Peri M, Iacono F, Barraco N, Perez A, Viscardi G, Cutaia S, Russo TDB, Anwar Z, Incorvaia L, Fulfaro F, Vieni S, Pantuso G, Graceffa G, Russo A, Galvano A, Bazan V. Gristina V, et al. Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31. Crit Rev Oncol Hematol. 2023. PMID: 36596401 Free article. Review.

152

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.

Dai J, Liu X, Li J, Qu T, Cui Y, Jin S, Zhang E, Guo R. Dai J, et al. Thorac Cancer. 2023 Feb;14(6):535-543. doi: 10.1111/1759-7714.14783. Epub 2023 Jan 2. Thorac Cancer. 2023. PMID: 36594109 Free PMC article. Review.

153

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.

Meri-Abad M, Moreno-Manuel A, García SG, Calabuig-Fariñas S, Pérez RS, Herrero CC, Jantus-Lewintre E. Meri-Abad M, et al. Crit Rev Oncol Hematol. 2023 Feb;182:103891. doi: 10.1016/j.critrevonc.2022.103891. Epub 2022 Dec 21. Crit Rev Oncol Hematol. 2023. PMID: 36565893 Free article. Review.

154

Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer.

Mendes AS, Romão R, Febra J, Azevedo SX, Fidalgo P, Araújo A. Mendes AS, et al. Thorac Cancer. 2023 Feb;14(5):437-441. doi: 10.1111/1759-7714.14779. Epub 2022 Dec 20. Thorac Cancer. 2023. PMID: 36539276 Free PMC article. Review.

155

Recent advances in ginsenosides against respiratory diseases: Therapeutic targets and potential mechanisms.

Ding L, Qi H, Wang Y, Zhang Z, Liu Q, Guo C, Liu J, Chen Z, Li J, Chen J, Huang Q, Zhao D, Wang Z, Li X. Ding L, et al. Biomed Pharmacother. 2023 Feb;158:114096. doi: 10.1016/j.biopha.2022.114096. Epub 2022 Dec 8. Biomed Pharmacother. 2023. PMID: 36502752 Free article. Review.

156

SMARCA4: Current status and future perspectives in non-small-cell lung cancer.

Tian Y, Xu L, Li X, Li H, Zhao M. Tian Y, et al. Cancer Lett. 2023 Feb 1;554:216022. doi: 10.1016/j.canlet.2022.216022. Epub 2022 Nov 28. Cancer Lett. 2023. PMID: 36450331 Free article. Review.

157

How the histological structure of some lung cancers shaped almost 70 years of radiobiology.

Worth KR, Papandreou I, Hammond EM. Worth KR, et al. Br J Cancer. 2023 Feb;128(3):407-412. doi: 10.1038/s41416-022-02041-9. Epub 2022 Nov 7. Br J Cancer. 2023. PMID: 36344595 Free PMC article. Review.

158

Lobe-specific lymph node dissection in early-stage non-small-cell lung cancer: An overview.

Peng L, Shang QW, Deng HY, Liu ZK, Li W, Wang Y. Peng L, et al. Asian J Surg. 2023 Feb;46(2):683-687. doi: 10.1016/j.asjsur.2022.07.042. Epub 2022 Jul 30. Asian J Surg. 2023. PMID: 35918226 Free article. Review.

159

The use of the mean computed-tomography value to predict the invasiveness of ground-glass nodules: A meta-analysis.

He S, Chen C, Wang Z, Yu X, Liu S, Huang Z, Chen C, Liang Z, Chen C. He S, et al. Asian J Surg. 2023 Feb;46(2):677-682. doi: 10.1016/j.asjsur.2022.07.031. Epub 2022 Jul 19. Asian J Surg. 2023. PMID: 35864044 Free article. Review.

160

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities.

Zubair T, Bandyopadhyay D. Zubair T, et al. Int J Mol Sci. 2023 Jan 31;24(3):2651. doi: 10.3390/ijms24032651. Int J Mol Sci. 2023. PMID: 36768973 Free PMC article. Review.

161

The human microbiome: A promising target for lung cancer treatment.

Sun Y, Wen M, Liu Y, Wang Y, Jing P, Gu Z, Jiang T, Wang W. Sun Y, et al. Front Immunol. 2023 Jan 30;14:1091165. doi: 10.3389/fimmu.2023.1091165. eCollection 2023. Front Immunol. 2023. PMID: 36817461 Free PMC article. Review.

162

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.

Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA. Perrino M, et al. Front Immunol. 2023 Jan 27;14:1121557. doi: 10.3389/fimmu.2023.1121557. eCollection 2023. Front Immunol. 2023. PMID: 36776840 Free PMC article. Review.

163

T lymphocyte cell: A pivotal player in lung cancer.

Wu Y, Yuan M, Wang C, Chen Y, Zhang Y, Zhang J. Wu Y, et al. Front Immunol. 2023 Jan 27;14:1102778. doi: 10.3389/fimmu.2023.1102778. eCollection 2023. Front Immunol. 2023. PMID: 36776832 Free PMC article. Review.

164

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.

Rocco D, Sapio L, Della Gravara L, Naviglio S, Gridelli C. Rocco D, et al. Int J Mol Sci. 2023 Jan 26;24(3):2433. doi: 10.3390/ijms24032433. Int J Mol Sci. 2023. PMID: 36768754 Free PMC article. Review.

165

Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis.

Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Ando K, et al. Int J Mol Sci. 2023 Jan 23;24(3):2242. doi: 10.3390/ijms24032242. Int J Mol Sci. 2023. PMID: 36768562 Free PMC article. Review.

166

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

Du Z, Sun J, Zhang Y, Hesilaiti N, Xia Q, Cui H, Fan N, Xu X. Du Z, et al. Biomolecules. 2023 Jan 20;13(2):210. doi: 10.3390/biom13020210. Biomolecules. 2023. PMID: 36830579 Free PMC article. Review.

167

Current status of and progress in the treatment of malignant pleural effusion of lung cancer.

Zhao Y, Yu L, Wang L, Wu Y, Chen H, Wang Q, Wu Y. Zhao Y, et al. Front Oncol. 2023 Jan 20;12:961440. doi: 10.3389/fonc.2022.961440. eCollection 2022. Front Oncol. 2023. PMID: 36818672 Free PMC article. Review.

168

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review.

Du HJ, Chen FF, Liu Y, Zhou Y. Du HJ, et al. Medicine (Baltimore). 2023 Jan 20;102(3):e32615. doi: 10.1097/MD.0000000000032615. Medicine (Baltimore). 2023. PMID: 36701708 Free PMC article. Review.

169

Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data.

Marin-Acevedo JA, Pellini B, Kimbrough EO, Hicks JK, Chiappori A. Marin-Acevedo JA, et al. Cancers (Basel). 2023 Jan 19;15(3):629. doi: 10.3390/cancers15030629. Cancers (Basel). 2023. PMID: 36765587 Free PMC article. Review.

170

Endobronchial metastasis secondary to occulting renal cell carcinoma: literature review and a rare case report.

Abdul Rahman SA, Abdul Rahman A, Rajab S, Mansour S, Mansour M, Salloum E, Alshehabi Z. Abdul Rahman SA, et al. BMC Pulm Med. 2023 Jan 19;23(1):28. doi: 10.1186/s12890-023-02320-y. BMC Pulm Med. 2023. PMID: 36653795 Free PMC article. Review.

171

Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature.

Bruni A, Bertolini F, D'Angelo E, Guaitoli G, Imbrescia J, Cappelli A, Guidi G, Stefani A, Dominici M, Lohr F. Bruni A, et al. Int J Mol Sci. 2023 Jan 18;24(3):1892. doi: 10.3390/ijms24031892. Int J Mol Sci. 2023. PMID: 36768209 Free PMC article. Review.

172

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.

Godoy LA, Chen J, Ma W, Lally J, Toomey KA, Rajappa P, Sheridan R, Mahajan S, Stollenwerk N, Phan CT, Cheng D, Knebel RJ, Li T. Godoy LA, et al. Biomark Res. 2023 Jan 18;11(1):7. doi: 10.1186/s40364-022-00444-7. Biomark Res. 2023. PMID: 36650586 Free PMC article. Review.

173

Management of Lung Cancer in the Patient with Interstitial Lung Disease.

Frank AJ, Dagogo-Jack I, Dobre IA, Tait S, Schumacher L, Fintelmann FJ, Fingerman LM, Keane FK, Montesi SB. Frank AJ, et al. Oncologist. 2023 Jan 18;28(1):12-22. doi: 10.1093/oncolo/oyac226. Oncologist. 2023. PMID: 36426803 Free PMC article. Review.

174

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer.

Ortega MA, Pekarek L, Navarro F, Fraile-Martínez O, García-Montero C, Álvarez-Mon MÁ, Diez-Pedrero R, Boyano-Adánez MDC, Guijarro LG, Barrena-Blázquez S, Gómez-Lahoz AM, Haro S, Arroyo M, Monserrat J, Saez MA, Alvarez-Mon M. Ortega MA, et al. J Pers Med. 2023 Jan 17;13(2):167. doi: 10.3390/jpm13020167. J Pers Med. 2023. PMID: 36836402 Free PMC article. Review.

175

Dietary Phytochemicals as Potential Chemopreventive Agents against Tobacco-Induced Lung Carcinogenesis.

Ding Y, Hou R, Yu J, Xing C, Zhuang C, Qu Z. Ding Y, et al. Nutrients. 2023 Jan 17;15(3):491. doi: 10.3390/nu15030491. Nutrients. 2023. PMID: 36771198 Free PMC article. Review.

176

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer.

Chicas-Sett R, Castilla Martinez J, Hernández Blanquisett A, Zafra J, Pastor-Peidro J. Chicas-Sett R, et al. Front Oncol. 2023 Jan 16;12:1092875. doi: 10.3389/fonc.2022.1092875. eCollection 2022. Front Oncol. 2023. PMID: 36727053 Free PMC article. Review.

177

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer.

Chhouri H, Alexandre D, Grumolato L. Chhouri H, et al. Cancers (Basel). 2023 Jan 13;15(2):504. doi: 10.3390/cancers15020504. Cancers (Basel). 2023. PMID: 36672453 Free PMC article. Review.

178

Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review.

Li N, Wan Z, Lu D, Chen R, Ye X. Li N, et al. Front Immunol. 2023 Jan 10;13:1088683. doi: 10.3389/fimmu.2022.1088683. eCollection 2022. Front Immunol. 2023. PMID: 36703977 Free PMC article. Review.

179

Advances in Lung Cancer Treatment Using Nanomedicines.

Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, Singh SK, Chellappan DK, Gupta G, Prasher P, Dua K, Kumar D. Sharma A, et al. ACS Omega. 2022 Dec 29;8(1):10-41. doi: 10.1021/acsomega.2c04078. eCollection 2023 Jan 10. ACS Omega. 2022. PMID: 36643475 Free PMC article. Review.

180

The role of serine metabolism in lung cancer: From oncogenesis to tumor treatment.

Zhou X, Tian C, Cao Y, Zhao M, Wang K. Zhou X, et al. Front Genet. 2023 Jan 9;13:1084609. doi: 10.3389/fgene.2022.1084609. eCollection 2022. Front Genet. 2023. PMID: 36699468 Free PMC article. Review.

181

Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes-A Case Report with Literature Review.

Grenda A, Krawczyk P, Targowska-Duda KM, Kieszko R, Paśnik I, Milanowski J. Grenda A, et al. Int J Mol Sci. 2023 Jan 7;24(2):1195. doi: 10.3390/ijms24021195. Int J Mol Sci. 2023. PMID: 36674722 Free PMC article. Review.

182

Subsegmentectomy versus segmentectomy resection for the treatment of operable patients with stage IA non-small cell lung cancer: A meta-analysis.

Song L, Li S, Hao X, Jin R, Li W, Zhang M, Wang J, Zhou S, Ma T, Xu S. Song L, et al. Front Surg. 2023 Jan 6;9:1060507. doi: 10.3389/fsurg.2022.1060507. eCollection 2022. Front Surg. 2023. PMID: 36684370 Free PMC article. Review.

183

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?

Lee SM, Lee S, Cho HW, Min KJ, Hong JH, Song JY, Lee JK, Lee NW. Lee SM, et al. Int J Mol Sci. 2023 Jan 4;24(2):974. doi: 10.3390/ijms24020974. Int J Mol Sci. 2023. PMID: 36674491 Free PMC article. Review.

184

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.

Palmieri M, Frullanti E. Palmieri M, et al. Med Sci (Basel). 2023 Jan 4;11(1):8. doi: 10.3390/medsci11010008. Med Sci (Basel). 2023. PMID: 36649045 Free PMC article. Review.

185

A Winning New Combination? Toward Clinical Application in Oncology.

Maqsood Q, Sumrin A, Iqbal M, Hussain N, Mahnoor M, Zafar Saleem M, Perveen R. Maqsood Q, et al. Cancer Control. 2023 Jan-Dec;30:10732748231175240. doi: 10.1177/10732748231175240. Cancer Control. 2023. PMID: 37166227 Free PMC article. Review.

186

Current status of pancreatic cancer with oligometastasis.

Chapa-Azuela Ó, Corona-Torres MJ, Ayala-Moreno EA, Arroyo-Paredes PS, Pérez-Torres E, Rodríguez-Báez A, Montalvo-Javé EE. Chapa-Azuela Ó, et al. Cir Cir. 2023;91(2):262-267. doi: 10.24875/CIRU.22000364. Cir Cir. 2023. PMID: 37084317 Free article. Review. English.

187

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer.

Yu L, Wang R, Zhao Y, Wu Y, Wang L, Chen H, He Z, Wang Q, Wu Y. Yu L, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231168466. doi: 10.1177/15330338231168466. Technol Cancer Res Treat. 2023. PMID: 37078129 Free PMC article. Review.

188

Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy.

Liu Y, Cheng W, Xin H, Liu R, Wang Q, Cai W, Peng X, Yang F, Xin H. Liu Y, et al. Cancer Nanotechnol. 2023;14(1):28. doi: 10.1186/s12645-023-00174-x. Epub 2023 Mar 28. Cancer Nanotechnol. 2023. PMID: 37009262 Free PMC article. Review.

189

Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.

Xu H, Ming P, Zhao Z, Zhao N, Zhou D, Tang X, Cao D. Xu H, et al. Integr Cancer Ther. 2023 Jan-Dec;22:15347354231164584. doi: 10.1177/15347354231164584. Integr Cancer Ther. 2023. PMID: 36998207 Free PMC article.

190

Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).

Cavalieri S, Vitolo V, Barcellini A, Ronchi S, Facoetti A, Campo C, Klersy C, Molinelli S, Agustoni F, Ferretti VV, Silvestri A, Platania M, Vecchio MD, Durante M, Helm A, Fournier C, Braud F, Pedrazzoli P, Orlandi E, Licitra L. Cavalieri S, et al. Future Oncol. 2023 Jan;19(3):193-203. doi: 10.2217/fon-2022-0503. Epub 2023 Mar 28. Future Oncol. 2023. PMID: 36974574 Free article. Review.

191

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer.

Mansur A, Garg T, Camacho JC, Habibollahi P, Edward Boas F, Khorshidi F, Buethe J, Nezami N. Mansur A, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231164193. doi: 10.1177/15330338231164193. Technol Cancer Res Treat. 2023. PMID: 36942407 Free PMC article. Review.

192

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.

Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. Nagasaka M, et al. Future Oncol. 2023 Jan;19(2):123-135. doi: 10.2217/fon-2022-1059. Epub 2023 Mar 6. Future Oncol. 2023. PMID: 36877099 Free article. Review.

193

Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.

Tsuji S, Imai K. Tsuji S, et al. Proc Jpn Acad Ser B Phys Biol Sci. 2023;99(2):39-47. doi: 10.2183/pjab.99.003. Proc Jpn Acad Ser B Phys Biol Sci. 2023. PMID: 36775341 Free PMC article. Review.

194

Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy.

Ghareghomi S, Atabaki V, Abdollahzadeh N, Ahmadian S, Hafez Ghoran S. Ghareghomi S, et al. Adv Pharm Bull. 2023 Jan;13(1):24-35. doi: 10.34172/apb.2023.003. Epub 2021 Oct 9. Adv Pharm Bull. 2023. PMID: 36721812 Free PMC article. Review.

195

Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment.

Miquelotti LB, Sari MHM, Ferreira LM. Miquelotti LB, et al. Adv Pharm Bull. 2023 Jan;13(1):88-95. doi: 10.34172/apb.2023.007. Epub 2021 Oct 10. Adv Pharm Bull. 2023. PMID: 36721805 Free PMC article. Review.

196

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.

Li T, Yang WY, Liu TT, Li Y, Liu L, Zheng X, Zhao L, Zhang F, Hu Y. Li T, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221148802. doi: 10.1177/15330338221148802. Technol Cancer Res Treat. 2023. PMID: 36628459 Free PMC article. Review.

197

Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.

Caliman E, Fancelli S, Petroni G, Gatta Michelet MR, Cosso F, Ottanelli C, Mazzoni F, Voltolini L, Pillozzi S, Antonuzzo L. Caliman E, et al. Lung Cancer. 2023 Jan;175:88-100. doi: 10.1016/j.lungcan.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

899 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

899 results

Results by year